Henry Schein Stock Rating Reaffirmed by Zacks (HSIC)
Henry Schein (NASDAQ:HSIC)‘s stock had its “neutral” rating reiterated by Zacks in a report released on Friday. They currently have a $125.00 target price on the stock. Zacks‘s price objective would indicate a potential upside of 4.65% from the company’s current price.
Zacks’ analyst wrote, “Henry Schein’s adjusted EPS of $1.35 in the second-quarter of 2014 increased 9.8% year over year and also beat the Zacks Consensus Estimate by 1.5%. Revenues rose 9.3% to $2.62 billion, edging past the Zacks Consensus Estimate by 1.8%. Animal Health continued to perform well while the core dental business picked up. The recent strategic acquisitions are expected to add value to the business. With the animal health market growing at a rapid pace and showcasing favorable trends, we are confident about further sales improvement. However, the overall macroeconomic uncertainty remains as overhang. Further, intense competition and currency fluctuations warrant caution. Moreover, as GPOs gain prominence, pricing pressure is inevitable. We still believe that the company’s diversified distribution business offers resilience against macroeconomic volatility. Thus, we remain Neutral on the stock. “
Henry Schein (NASDAQ:HSIC) traded up 0.22% on Friday, hitting $119.71. The stock had a trading volume of 106,690 shares. Henry Schein has a 52-week low of $100.64 and a 52-week high of $120.99. The stock’s 50-day moving average is $118.2 and its 200-day moving average is $117.5. The company has a market cap of $10.155 billion and a P/E ratio of 23.00.
Henry Schein (NASDAQ:HSIC) last released its earnings data on Monday, August 4th. The company reported $1.35 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.33 by $0.02. The company had revenue of $2.60 billion for the quarter, compared to the consensus estimate of $2.56 billion. During the same quarter in the previous year, the company posted $1.23 earnings per share. The company’s revenue for the quarter was up 9.3% on a year-over-year basis. Analysts expect that Henry Schein will post $5.38 EPS for the current fiscal year.
Several other analysts have also recently commented on the stock. Analysts at Credit Suisse reiterated a “neutral” rating on shares of Henry Schein in a research note on Tuesday, August 5th. They now have a $121.00 price target on the stock, up previously from $120.00. Separately, analysts at Leerink Swann raised their price target on shares of Henry Schein from $120.00 to $127.00 in a research note on Tuesday, August 5th. They now have a “market perform” rating on the stock. Finally, analysts at ISI Group cut their price target on shares of Henry Schein from $130.00 to $127.00 in a research note on Monday, August 4th. They now have a “neutral” rating on the stock. Four equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus target price of $123.60.
Henry Schein, Inc is a provider of health care products and services to office-based practitioners. The Company conducts its business through two segments: healthcare distribution and technology.
To view Zacks’ full report, visit Zacks’ official website.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.